China's huge population and growing commitment to health care are predicted to make the country the world's second-largest consumer of pharmaceuticals by 2015. However, despite the size of the market, the large numbers of treatment-naÃ¯ve patients, and the necessity of collecting clinical trial data patients in China before the Chinese State Food and Drug Administration (SFDA) will approve a drug for sale in their country, only 152 international, multi-center clinical trials were initiated in China in 2010 (three percent of the world-wide total).
This white paper by PPD explores the reasons for the gap between supply and demand and provides an overview of the opportunities and challenges of conducting clinical trials in China. To find out more, click here to download this whitepaper now!
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services, with offices in 44 countries and more than 11,000 professionals worldwide. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. As one of the largest global CROs in Asia Pacific, PPD offers a complete range of services locally and employs more than 1,400 professionals in 13 countries.